No profile data available.
Arcutis Biotherapeutics, Inc. (ARQT) is a healthcare company in the skin treatment pharmaceuticals industry, based in Westlake Village, United States, with about 354 full-time employees.
It reported revenue of $196.54 million for fiscal year 2024, up 229.7% from fiscal year 2023, and net income of -$140.04 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $99.22 million, up 121.7% from a year before. Its market capitalization was $3.34 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Arcutis Biotherapeutics reported $196.54 million in revenue for fiscal year 2024, up 229.7% from $59.61 million in fiscal year 2023. In Q3 2025 revenue was $99.22 million.
$3.34 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Krystal Biotech, Inc. (KRYS), Kymera Therapeutics, Inc. (KYMR), Oruka Therapeutics, Inc. (ORKA), Almirall, S.a. (ALMRY).